Search Results

You are looking at 141 - 150 of 219 items for :

  • Refine by Access: All x
Clear All
Full access

Chimeric Antigen Receptor T-Cell Therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen

duration of 1 week. The first sign of CRS is usually fever, which can progress to hypotension and/or hypoxia; other signs and symptoms may include arrhythmias, coagulopathies, tachycardia, and other organ toxicities. 62 , 63 Management strategies have been

Full access

Role of Immune Therapies for Myeloma

Jacalyn Rosenblatt and David Avigan

risk of death or disease progression compared with the control arm. 55 Adverse events related to elotuzumab have included lymphopenia and infusion reactions, such as fevers and hypertension. 55 An alternative strategy has been the development of NK

Full access

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

J. Sybil Biermann, Warren Chow, Damon R. Reed, David Lucas, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, G. Thomas Budd, William T. Curry, Aarati Didwania, Nicola Fabbri, Francis J. Hornicek, Joseph B. Kuechle, Dieter Lindskog, Joel Mayerson, Sean V. McGarry, Lynn Million, Carol D. Morris, Sujana Movva, Richard J. O'Donnell, R. Lor Randall, Peter Rose, Victor M. Santana, Robert L. Satcher, Herbert Schwartz, Herrick J. Siegel, Katherine Thornton, Victor Villalobos, Mary Anne Bergman, and Jillian L. Scavone

attention because of localized pain or swelling. Unlike other bone sarcomas, constitutional symptoms such as fever, weight loss, and fatigue are occasionally noted at presentation. Abnormal laboratory studies may include elevated serum lactate dehydrogenase

Full access

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

Al B. Benson III, Michael I. D'Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Chandrakanth Are, Daniel B. Brown, Daniel T. Chang, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Andrew X. Zhu, Karin G. Hoffmann, and Susan Darlow

vary across studies. 81 , 82 A postembolization syndrome involving fever, abdominal pain, and intestinal ileus is relatively common in patients undergoing these procedures. 81 , 82 TAE or TACE can increase the risk of liver failure, hepatic necrosis

Full access

Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer

Ryan D. Gentzler and Jyoti D. Patel

factors that preclude the use of bevacizumab, and the desire to avoid alopecia and neutropenic fever. For most patients with NS-NSCLC, optimal first-line treatment is a combination of a platinum drug with pemetrexed alone, pemetrexed and bevacizumab, or

Full access

Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina

pediatric population are used to justify interferon use in the pediatric melanoma population. In adults, the side-effect profile deters many patients from receiving interferon: toxicity such as fevers, fatigue, myalgias/arthralgias, and depression limit

Full access

Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 11 Trillet-Lenoir V Green J Manegold C

Full access

Malignant Pleural Mesothelioma

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary Pinder Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

form without the express written permission of NCCN®. Diagnosis Patients with suspected MPM often have symptoms (e.g., dyspnea and chest pain) and can also have pleural effusion, cough, chest wall mass, weight loss, fever, and sweating

Full access

The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider

Patients are rarely symptomatic; however, some may present with fever. Other more common causes of renal dysfunction, such as dehydration or exposure to nephrotoxins like nonsteroidal anti-inflammatory drugs, contrast agents, bisphosphonates, and proton

Full access

Integrating Immune Therapies for the Treatment of Multiple Myeloma

Lekha Mikkilineni and Surbhi Sidana

Standard of Care Products CRS occurs due to immune activation, resulting in release of cytokines and immunologic proteins. 21 Common clinical manifestations of CRS include fever, tachycardia, hypotension, and hypoxia. 21 , 22 Severity of CRS depends